Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 3/20 | 1.00 |
| ▸ | RELA | Q04206 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804219 | 0.80 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL18180861 | 0.80 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL28253323 | 0.80 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL7718014 | 0.77 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL4020988 | 0.77 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL3642839 | 0.77 | MAPT (0.88) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL12793737 | 0.75 | MEN1 (0.64) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL28242755 | 0.75 | NPC1 (0.59) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL1687871 | 0.73 | HDAC3 (0.64) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL6814592 | 0.73 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180195066-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH | RXI PHARMACEUTICALS CORPORATION (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195066-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH | SOD1, POLRMT, SMN1; SMN2 | RAB9A 2384/4885NPC1 1585/4885SMN1; SMN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.